China Healthcare: Macro Themes
472 Views18 Dec 2020 20:56
This Insight summarizes the takeaways from a recent China healthcare industry conference. There is much talk of pressures on the industry, but innovative companies will benefit from policy tailwinds.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 11-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
Price Chart(Sign Up to Access)
- BeiGene: Novartis Grabs Tislelizumab Rights13 Jan 2021
- BeiGene: Cancer Treatment in China--The Underestimated Opportunity10 Jan 2021
- Microport Cardioflow: Winning in TAVR10 Jan 2021
- Eddingpharm: First Impressions15 Dec 2020
- Jacobio: Updated Valuation and Other Thoughts04 Dec 2020
- Asian Healthcare - Coming of Age26 Nov 2020
x